MMMT
MCID: MLG098
MIFTS: 36

Malignant Mixed Mullerian Tumor (MMMT) malady

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Malignant Mixed Mullerian Tumor

Aliases & Descriptions for Malignant Mixed Mullerian Tumor:

Name: Malignant Mixed Mullerian Tumor 50
Carcinosarcoma 50 52 69
Mixed Tumor, Mullerian 50 69
Mixed Tumor, Not Otherwise Specified 69
Malignant Mixed Mesodermal Tumor 69
Mixed Mullerian Tumor 50
Mixed Tumor Mullerian 52
Mmmt 50

Classifications:



Summaries for Malignant Mixed Mullerian Tumor

NIH Rare Diseases : 50 a malignant mixed müllerian tumor (mmmt), also called a carcinosarcoma, is a type of cancer that contains two types of cells, known as the adenocarcinoma and sarcoma types. these tumors usually develop in tissues of the female genital tract and are associated with a poor outcome. the majority of these tumors arise in the uterus, though they can also occur in the ovaries, fallopian tubes, and cervix. very rarely, mmmts can develop in the female peritoneum (lining of the abdominal wall). last updated: 12/6/2011

MalaCards based summary : Malignant Mixed Mullerian Tumor, also known as carcinosarcoma, is related to papilloma and ovarian carcinosarcoma. An important gene associated with Malignant Mixed Mullerian Tumor is VIM (Vimentin), and among its related pathways/superpathways are Cytoskeleton remodeling Neurofilaments and Cytoskeletal Signaling. The drugs Carboplatin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include ovary, uterus and cervix, and related phenotype is muscle.

Related Diseases for Malignant Mixed Mullerian Tumor

Diseases related to Malignant Mixed Mullerian Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
id Related Disease Score Top Affiliating Genes
1 papilloma 29.8 MUC1 PGR
2 ovarian carcinosarcoma 11.8
3 cervical carcinosarcoma 11.1
4 vaginal carcinosarcoma 11.1
5 fallopian tube carcinosarcoma 11.1
6 13q12.3 microdeletion syndrome 10.2 DES VIM
7 inflammatory linear verrucous epidermal nevus 10.2 DES VIM
8 osteomyelitis 10.2 DES VIM
9 congenital myasthenic syndrome 10.2 DES VIM
10 malignant dermis tumor 10.2 DES VIM
11 urethral cancer 10.2 DES VIM
12 intestinal obstruction 10.2 DES VIM
13 cavernous sinus meningioma 10.2 DES VIM
14 male reproductive system disease 10.2 DES VIM
15 male urethral cancer 10.2 DES VIM
16 dyslexia 10.2 DES VIM
17 glomangioma 10.2 DES VIM
18 skin glomus tumor 10.2 DES VIM
19 t-cell childhood lymphoblastic lymphoma 10.1 DES VIM
20 intracranial sinus thrombosis 10.1 KIT VIM
21 his bundle tachycardia 10.1 PGR VIM
22 alcohol-induced mental disorder 10.1 KIT VIM
23 stomach diverticulosis 10.1 KIT VIM
24 carbon monoxide-induced parkinsonism 10.1 DES KIT
25 atypical lipomatous tumor 10.1 KIT PGR
26 testis sarcoma 10.1 DES KIT
27 cystitis 10.1 PGR VIM
28 skin angiosarcoma 10.1 KIT PGR
29 hyperpituitarism 10.1 DES VIM
30 caroli disease 10.1 DES VIM
31 intestinal neuroendocrine benign tumor 10.1 KIT PGR
32 vulva basal cell carcinoma 10.1 KIT PGR
33 juvenile xanthogranuloma 10.1 DES VIM
34 middle ear adenocarcinoma 10.1 KIT PGR
35 pustulosis palmaris et plantaris 10.1 DES KIT
36 advanced sleep-phase syndrome, familial, 2 10.1 DES VIM
37 ovarian embryonal carcinoma 10.1 KIT PGR
38 postpartum depression 10.1 KIT PGR
39 laryngeal neuroendocrine tumor 10.1 KIT PGR
40 reactive arthritis 10.1 KIT PGR
41 lipoadenoma 10.1 KIT VIM
42 arthus reaction 10.1 KIT PGR
43 pneumonia 10.1 KIT PGR
44 neutrophil immunodeficiency syndrome 10.1 DES VIM
45 van regemorter pierquin vamos syndrome 10.1 DES KIT
46 immunodeficiency due to a classical component pathway complement deficiency 10.1 MUC1 VIM
47 autosomal recessive stickler syndrome 10.1 MUC1 VIM
48 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 10.1 MUC1 VIM
49 microinvasive cervical squamous cell carcinoma 10.1 MUC1 VIM
50 subglottis verrucous carcinoma 10.1 MUC1 VIM

Graphical network of the top 20 diseases related to Malignant Mixed Mullerian Tumor:



Diseases related to Malignant Mixed Mullerian Tumor

Symptoms & Phenotypes for Malignant Mixed Mullerian Tumor

MGI Mouse Phenotypes related to Malignant Mixed Mullerian Tumor:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 8.92 DES KIT PGR VIM

Drugs & Therapeutics for Malignant Mixed Mullerian Tumor

Drugs for Malignant Mixed Mullerian Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
2
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
6
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
7
Lenograstim Approved Phase 3,Phase 1 135968-09-1
8
Mesna Approved Phase 3,Phase 2 3375-50-6 598
9
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
10
Cyproheptadine Approved Phase 3 129-03-3 2913
11
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
13 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
14 Alkylating Agents Phase 3,Phase 2
15 Antimitotic Agents Phase 3,Phase 2,Phase 1
16 Antineoplastic Agents, Alkylating Phase 3,Phase 2
17 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
18 Isophosphamide mustard Phase 3,Phase 2
19 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
20 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
22 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
23 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
24 Neurotransmitter Agents Phase 3
25 Anti-Allergic Agents Phase 3
26 Antipruritics Phase 3
27 Dermatologic Agents Phase 3
28 Gastrointestinal Agents Phase 3
29 Histamine Antagonists Phase 3
30 Histamine H1 Antagonists Phase 3
31
Histamine Phosphate Phase 3 51-74-1 65513
32
Serotonin Phase 3 50-67-9 5202
33 Serotonin Agents Phase 3
34 Serotonin Antagonists Phase 3
35
Gemcitabine Approved Phase 2 95058-81-4 60750
36
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
37
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
38
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599, 9887054 43805
39
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
40
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
41
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
42
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
43
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
44
Belinostat Approved, Investigational Phase 1, Phase 2 866323-14-0
45
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
46
Metformin Approved Phase 2 657-24-9 14219 4091
47
nivolumab Approved Phase 2 946414-94-4
48
Everolimus Approved Phase 2 159351-69-6 6442177
49
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
50
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353

Interventional clinical trials:

(show top 50) (show all 74)
id Name Status NCT ID Phase
1 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
2 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3
3 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3
4 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
5 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
6 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
7 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
8 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2
9 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Unknown status NCT00511992 Phase 2
10 Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Unknown status NCT00838656 Phase 2
11 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
12 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2
13 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2
14 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2
15 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2
16 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2
17 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2
18 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2
19 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2
20 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2
21 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2
22 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2
23 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2
24 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
25 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2
26 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2
27 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2
28 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2
29 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2
30 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
31 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2
32 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2
33 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2
34 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2
35 A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus Completed NCT00231842 Phase 2
36 Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) Completed NCT00129727 Phase 2
37 Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer Completed NCT00392769 Phase 2
38 Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer Completed NCT00061308 Phase 2
39 A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment Completed NCT00421889 Phase 1, Phase 2
40 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Recruiting NCT03015129 Phase 2
41 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2
42 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2
43 Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Recruiting NCT01935934 Phase 2
44 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
45 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Active, not recruiting NCT01168232 Phase 2
46 Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Active, not recruiting NCT00416455 Phase 1, Phase 2
47 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Active, not recruiting NCT01010126 Phase 2
48 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2
49 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2
50 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Not yet recruiting NCT02923934 Phase 2

Search NIH Clinical Center for Malignant Mixed Mullerian Tumor

Genetic Tests for Malignant Mixed Mullerian Tumor

Anatomical Context for Malignant Mixed Mullerian Tumor

MalaCards organs/tissues related to Malignant Mixed Mullerian Tumor:

39
Ovary, Uterus, Cervix, Lung, Breast

Publications for Malignant Mixed Mullerian Tumor

Articles related to Malignant Mixed Mullerian Tumor:

(show top 50) (show all 54)
id Title Authors Year
1
Serous Carcinoma component championed by Heparin Binding-EGF Like Growth Factor (HB-EGF) Predisposing to Metastasis and Recurrence in Stage I Uterine Malignant Mixed Mullerian Tumor. ( 26980026 )
2016
2
Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor. ( 26711836 )
2015
3
Serous Ovarian Carcinoma Recurring as Malignant Mixed Mullerian Tumor. ( 26713165 )
2015
4
Extragenital malignant mixed Mullerian tumor in the incisional hernia - primary carcinosarcoma in the abdominal wall: case report. ( 26012132 )
2015
5
Endometrioid carcinoma infiltrating atypical leiomyoma: a mimicker of malignant mixed Mullerian tumor. ( 24943777 )
2014
6
Malignant mixed mullerian tumor of the ovary. ( 25404814 )
2014
7
F-18 fluorodeoxyglucose positron emission tomography/computed tomography in a rare case of recurrent malignant mixed mullerian tumor. ( 25191116 )
2014
8
Prolonged survival of a patient with pelvic recurrence of ovarian malignant mixed mullerian tumor after chemoradiotherapy. ( 25593719 )
2014
9
ANNA-1 (anti-Hu) associated sensory neuronopathy with malignant mixed mullerian tumor. ( 23536385 )
2013
10
Malignant mixed mullerian tumor: an immunohistochemical study. ( 22848863 )
2012
11
Malignant mixed mullerian tumor of endometrium coexisting with bilateral papillary serous adenocarcinoma of fallopian tube: a rare case report. ( 24293882 )
2012
12
Ovarian malignant mixed mullerian tumor with primitive neuroectodermal differentiation: case report with review of the literature. ( 20950943 )
2011
13
Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature. ( 21298439 )
2011
14
Malignant mixed Mullerian tumor of broad ligament with synchronous ovarian and endometrial carcinoma: a rare association. ( 21546752 )
2011
15
Uncommon manifestations of Endocervical Malignant Mixed Mullerian Tumor with Incidental Bilateral Fallopian Tube Carcinoma. ( 21701666 )
2011
16
Malignant mixed mullerian tumor of the cervix including components of a rhabdomyosarcoma: case report and literature review. ( 20882897 )
2010
17
Bilateral ovarian malignant mixed Mullerian tumor in a dog. ( 19176505 )
2009
18
Extra genital heterologous malignant mixed mullerian tumor of primary peritoneal origin. ( 19136793 )
2009
19
Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors. ( 19851197 )
2009
20
Homologous type of malignant mixed Mullerian tumor of the uterus presenting as a cervical mass. ( 19837648 )
2009
21
Biopsy-proven cerebellar metastasis from a malignant mixed mullerian tumor (MMMT) of the uterus: case report. ( 19480254 )
2009
22
Intracardiac metastasis of a Malignant Mixed Mullerian tumor (MMMT): progressive dyspnoea due to obstruction of the left atrium and the left ventricle without left ventricular dysfunction or primary lung disease. ( 19652943 )
2009
23
CT imaging of a primary malignant mixed mullerian tumor arising from the peritoneum. ( 18760728 )
2008
24
Malignant mixed mullerian tumor of the urinary bladder in a 73 year old woman. ( 18559304 )
2008
25
Primary malignant mixed mullerian tumor of the uterus: findings on sonography, CT, and gadolinium-enhanced MRI. ( 18562759 )
2008
26
Malignant mixed mullerian tumor of the vagina: case report with review of the literature, immunohistochemical study, and evaluation for human papilloma virus. ( 17640554 )
2007
27
Primary malignant mixed Mullerian tumor arising in the rectosigmoid. ( 16612719 )
2006
28
Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. ( 16407622 )
2006
29
Malignant mixed mullerian tumor in a rabbit (Oryctolagus cuniculus): case report with immunohistochemistry. ( 16847001 )
2006
30
Diagnostic dilemma in a case of malignant mixed mullerian tumor of the cervix. ( 16813659 )
2006
31
Paraneoplastic subacute sensory neuronopathy secondary to a malignant mixed mullerian tumor. ( 16449165 )
2006
32
Malignant mixed mullerian tumor (MMMT) of the cervix. ( 15863143 )
2005
33
Primary malignant mixed mullerian tumor of the vagina immunohistochemically confirmed. ( 14735374 )
2005
34
Primary peritoneal carcinosarcoma (malignant mixed mullerian tumor): Report of a case with five-year disease free survival after surgery and chemoradiation and a review of literature. ( 16227168 )
2005
35
Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene. ( 15863610 )
2005
36
Presentation with superior vena cava syndrome secondary to solitary lung metastasis mimicking primary lung cancer following resection of a uterine malignant mixed mullerian tumor: brief case report. ( 15653218 )
2005
37
Malignant mixed Mullerian tumor of the fimbriated end of the fallopian tube: origin as an intraepithelial carcinoma. ( 15790462 )
2005
38
Comment on "Malignant mixed Mullerian tumor of the ovary: an argument for BRCA3 or a coincidental cluster of unconnected cancer". ( 15582005 )
2004
39
Malignant mixed Mullerian tumor of the ovary growing into an inguinal hernia sac: report of a case. ( 14513334 )
2003
40
Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component. ( 14599882 )
2003
41
Malignant mixed mullerian tumor of the ovary and bilateral breast cancer: an argument for BRCA3, or a coincidental cluster of unconnected cancers? ( 14599878 )
2003
42
Malignant mixed Mullerian tumor of the uterine cervix with neuroendocrine differentiation. ( 11975686 )
2002
43
Malignant mixed mullerian tumor of the ovary: report of four cases. ( 11321500 )
2001
44
Good response of malignant mixed mullerian tumor of the ovary to paclitaxel and cisplatin chemotherapy. ( 10609493 )
1999
45
Malignant Mixed Mullerian Tumor of the Extra-genital Coelomic Epithelium: Report of Two Cases. ( 11173640 )
1997
46
Myasthenia gravis associated with malignant mixed Mullerian tumor of the uterus. ( 9062162 )
1997
47
Malignant mixed mullerian tumor of the female peritoneum: treatment and outcome of three cases. ( 9190987 )
1997
48
Extragenital malignant mixed mullerian tumor. ( 8386082 )
1993
49
Complex karyotypic aberrations, including i(12p), in malignant mixed mullerian tumor of uterus. ( 1317254 )
1992
50
Malignant mixed mullerian tumor arising in extragenital endometriosis: report of a case and review of the literature. ( 3002920 )
1986

Variations for Malignant Mixed Mullerian Tumor

Expression for Malignant Mixed Mullerian Tumor

Search GEO for disease gene expression data for Malignant Mixed Mullerian Tumor.

Pathways for Malignant Mixed Mullerian Tumor

Pathways related to Malignant Mixed Mullerian Tumor according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.36 DES VIM
2 11.28 DES MUC1 VIM
3 11.24 DES KIT
4 11.01 DES VIM
5
Show member pathways
10.61 DES VIM

GO Terms for Malignant Mixed Mullerian Tumor

Biological processes related to Malignant Mixed Mullerian Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 muscle filament sliding GO:0030049 8.96 DES VIM
2 intermediate filament organization GO:0045109 8.62 DES VIM

Molecular functions related to Malignant Mixed Mullerian Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 structural constituent of cytoskeleton GO:0005200 8.62 DES VIM

Sources for Malignant Mixed Mullerian Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....